Major Analysis Finds Prescription Drugs and Lifestyle Changes, Not Supplements, Reduce Biological Age

On September 26, 2026, researchers from the Yale School of Medicine published a comprehensive analysis of 51 clinical trials, revealing that prescription medications and lifestyle changes consistently reduce biological age markers, while over-the-counter supplements largely fail to do so. The study, published in Nature Medicine, evaluated more than 110 DNA methylation biomarkers across thousands of participants to determine which interventions actually slow the cellular aging process. By aggregating data from diverse human trials, the research team created the first evidence-based roadmap for measuring how the body responds to longevity treatments, cutting through the noise of the wellness industry to identify what genuinely works.[2][4][5]

The Yale team, led by computational biologist Raghav Sehgal and psychiatrist Albert Higgins-Chen, utilized 16 distinct "epigenetic clocks" to measure biological age. These clocks track chemical tags on DNA that change predictably over a human lifespan, offering a more accurate picture of cellular health than chronological age. By comparing blood samples taken before and after various interventions, the researchers were able to quantify the exact impact of different therapies. The biomarkers shifted more substantially among participants with existing diseases than among healthy volunteers, providing critical insight into how the body repairs itself when subjected to metabolic or inflammatory stress.[2][5]

Pharmacological interventions produced the largest and most consistent decreases in epigenetic age. The analysis highlighted three specific classes of prescription drugs: metformin, a first-line treatment for type 2 diabetes; semaglutide, a GLP-1 agonist prescribed for weight management and diabetes; and anti-TNF therapies, which are biologic medications used to control autoimmune inflammation. Across the 16 clocks used in the study, these medications significantly reversed cellular aging markers. The authors hypothesized that these robust effects stem from the drugs' ability to target foundational inflammation and metabolic pathways, essentially cooling the systemic stress that accelerates cellular decline.[1][2][5]

A separate, large-scale analysis of semaglutide provided concrete numbers on these organ-specific benefits. In a preprint study led by researcher Maria Dermit, analyzing proteomics from 10,052 participants across five placebo-controlled trials, researchers found that semaglutide reduced the biological age of the heart by two to four years. The drug also drove reductions of one to four years across kidney, brain, pancreas, and lung clocks over a 156-week follow-up period. These findings indicate that the effects of semaglutide on systemic biological frailty are time-dependent, with the most substantial reductions emerging beyond the first year of continuous treatment.[3]

The proteomic data suggested that these biological age changes accounted for 34 to 49 percent of semaglutide's protective effects on clinical outcomes, such as cardiovascular events. This indicates that the medication does not just manage weight or blood sugar, but fundamentally alters the systemic vulnerability of major organs over time. By mapping these changes, researchers demonstrated a reproducible remodeling of mortality-associated proteomic signatures across diverse populations, providing a clear mechanistic link between the drug and its widely reported cardiovascular benefits.[3]

In stark contrast to the prescription drugs, the Yale analysis demonstrated that over-the-counter supplements did not significantly reduce epigenetic age. The research group found that the data for supplements—including omega-3 fatty acids, folate, and various vitamins—was limited and inconsistent. While supplements remain valuable for treating specific nutritional deficiencies, the evidence does not support their use as broad anti-aging therapeutics. This finding challenges a significant portion of the anti-aging consumer market, which heavily promotes daily supplementation as a primary strategy for cellular longevity.[1][2][5]

Lifestyle interventions, however, proved highly effective. Programs combining regular exercise with a healthy diet consistently lowered epigenetic age across the board. The researchers noted that these benefits held true regardless of whether the specific eating plan was a Mediterranean, low-carbohydrate, or low-fat diet, reinforcing that fundamental movement and whole-food nutrition remain the most reliable foundations for a long health span. The data showed that these behavioral changes produced some of the most consistent responses across different biomarkers, validating decades of public health advice at the molecular level.[2][5]

For readers looking to optimize their health, the data offers a practical and reassuring takeaway: prioritize proven lifestyle habits over expensive supplement regimens. While the prescription drug results are robust, experts caution against healthy individuals seeking out metformin or semaglutide solely for anti-aging purposes. Because the biomarkers shifted more substantially among participants with existing diseases, the observed changes may partly reflect improvements in the underlying disease, inflammation, or metabolic health rather than a direct reversal of aging itself in an otherwise healthy system.[2][5]

This discrepancy suggests that the medications are correcting underlying dysfunction rather than acting as a universal fountain of youth. As the analysis noted, these findings should not be interpreted as meaning healthy people should take these prescription drugs simply to slow aging. The risks and side effects of pharmacological interventions must be weighed against their benefits, and currently, the data only supports their use in populations where a specific metabolic or inflammatory condition is already present and driving accelerated cellular aging.[1]

The true breakthrough of the Yale analysis lies in the validation of the epigenetic clocks themselves. Proving that a treatment extends human life typically requires decades of follow-up, making longevity research notoriously slow and expensive. By demonstrating that these DNA methylation biomarkers respond consistently to known interventions, researchers have unlocked a much faster method for testing future therapies. Scientists can now measure the efficacy of a new protocol in a matter of months, drastically accelerating the pace of geroscience.[2][5]

"For the first time we've shown that certain therapies have measurable impacts," Sehgal stated following the publication. "If these new biomarkers are eventually validated to predict long-term health, scientists will be able to evaluate anti-aging therapies much faster." The next phase of research will involve expanded testing in wider, more diverse groups of healthy volunteers to track how these cellular improvements translate into decades of extended health, ultimately moving the field closer to targeted, personalized longevity medicine that relies on hard data rather than guesswork.[2][5]